Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4
AssigneeHelmut Jonuleit
InventorsFranz-Josef Schneider, Christian Becker, Tobias Bopp, Helmut Jonuleit, Edgar Schmitt
Life of this patent
Estimating the term…
Abstract
The present invention relates specific activation of a regulatory T cell via a specific CD4 epitope and uses thereof, e.g. for the treatment of an autoimmune disease or an allergy or asthma or graft rejection or tolerance induction.
Claims35
A method for determining whether a substance can activate a Treg cell via interaction with the HIV-1 gp120-binding site of CD4, comprising:
- (a) pre-selecting a substance which can interact with the HIV-1 gp120-binding site of CD4,
- (b) providing a solution comprising a CD4+CD25+ Treg cell,
- (c) adding a pre-selected substance according to (a) under conditions which allow interaction of the substance with a CD4+CD25+ Treg cell,
- (d) measuring whether a CD4+CD25+ Treg cell has been activated, wherein an activated CD4+CD25+ Treg cell identifies the substance as a Treg cell activator.
A method according to claim 1 wherein in (d) of claim 16 the measuring whether a CD4+CD25+ Treg cell has been activated is determined by measuring the amount of intracellular cAMP and wherein an increased amount of intracellular cAMP is indicative for an activated CD4+CD25+ Treg cell and therewith identifies the substance as a Treg cell activator.
A method according to claim 1 wherein step (a) of claim 16 comprises:
- (a) providing a first solution comprising CD4,
- (b) providing a second solution comprising CD4,
- (c) adding to the first solution a substance to be tested and HIV-1 gp120 under conditions which allow binding of HIV-1 gp120 with CD4,
- (d) adding to the second solution HIV-1 gp120 under conditions like
- (c) allowing binding of HIV-1 gp120 with CD4,
- (e) measuring in the first and in the second solution whether the HIV-1 gp120 has bound to the CD4 wherein a reduced amount of bound HIV-1 gp120 in the first solution indicates that the substance can interact with HIV-1 gp120-binding site of CD4.
A method for determining whether a substance can activate a regulatory T cell (Treg) via interaction with the epitope as set forth in SEQ ID NO:
- 1 comprising:
- (a) providing a first solution comprising a CD4+CD25+ Treg cell,
- (b) adding a substance to be tested under conditions which allow interaction of the substance with a CD4+CD25+ Treg cell,
- (c) measuring whether a CD4+CD25+ Treg cell of the first solution has been activated,
- (d) providing a second solution comprising a CD4+CD25+ Treg cell,
- (e) adding the substance to be tested and a peptide comprising an amino acid sequence as set forth in SEQ ID NO:
- 1 under conditions like (b),
- (f) measuring whether a CD4+CD25+ Treg cell of the second solution has been activated,
- (g) comparing results obtained from (c) with those obtained from
- (f) wherein a reduced activation of (f) identifies the substance as a Treg cell activator which activates a CD4+CD25+ Treg cell via interaction with the epitope as set forth in SEQ ID NO:
- 1.
A method according to claim 19 wherein in step (e) of claim 34 the peptide used is selected from a group consisting of an isolated peptide spanning amino acid No. 1-31 of SEQ ID NO 1, No. 26 to 458 of SEQ ID NO.:
- 2, No. 26 to 419 of SEQ ID NO.:2, No. 26 to 207 of SEQ ID NO.:
- 2, No. 26 to 131 of SEQ ID NO.:
- 2 and No. 46 to 89 of SEQ ID NO.:
- 2.
A method according to claim 19 wherein in step (e) of claim 34 the peptide used is an isolated peptide spanning amino acid No. 1 to 31 of SEQ ID NO.:
- 1 and having additional up-stream and/or downstream amino acids with the prerequisite that the additional amino acids do not hinder binding of a substance to the amino acid stretch as set forth in SEQ ID No.:
- 1.
Dependencies are inferred from the claim text.